Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.
Mesa RA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2021)
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells
Masuda K. et al, (2021), JCI Insight
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W. et al, (2021), Br J Cancer, 124, 1661 - 1669
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Li J. et al, (2021), Cancer Discov, 11, 1212 - 1227
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA. et al, (2021), Blood Adv, 5, 2229 - 2236
NICE public health guidance update.
Blagden S. et al, (2021), J Public Health (Oxf), 43, e107 - e109
Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer
SIVAKUMAR S. et al, (2021), Molecular Biomarkers and Precision Medicine for Pancreatic, Liver and Biliary Tract Cancers
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.
Royston D. et al, (2021), Hematol Oncol Clin North Am, 35, 279 - 293
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ. et al, (2021), J Clin Oncol, 39, 1129 - 1138
Care of haematology patients in an overwhelmed healthcare system.
Willan J. et al, (2021), Br J Haematol, 193, 269 - 270
CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 96 - 96
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang P. et al, (2021), Cancer Res, 81, 1667 - 1680
Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 101 - 102
Modification of escalated beacopp with dacarbazine substitution reduces toxicity while maintaining efficacy for the treatment of advanced-stage Hodgkin lymphoma
Santarsieri A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 40 - 41
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A. et al, (2021), Br J Haematol, 193, 63 - 71
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Dalle S. et al, (2021), BMC Cancer
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Dalle S. et al, (2021), BMC Cancer
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C. et al, (2021), J Exp Med, 218